A Phase 1 interventional study of Orforglipron and Placebo in Obesity and Overweight, sponsored by Eli Lilly and Company. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-25.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing orforglipron in Obesity — 4 open to participants now, 10 under way, 9 of them phase 3. orforglipron · Obesity.
Among the 22 studies testing orforglipron in Obesity, this one is the 17th largest by enrollment, is one of 6 that started in 2025, is one of 6 in phase 1, and was the 15th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →4 of the 22 studies testing orforglipron in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Belgium, Brazil and 10 more countries
Ages 6–17
Eli Lilly and Company · Sites in United States, Israel, Italy and 3 more countries
Ages 12–17
Eli Lilly and Company · Sites in China
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18–80
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, orforglipron is the treatment under test here. Read study by study →
22 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 324 across the 22 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 22 have an industry lead sponsor. The 2 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
118 studies in Obesity by Eli Lilly and Company: 31 open now, 55 under way, 30 of them phase 3. Of 61 finished, 29 (48%) have results posted.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 87th largest by enrollment of the 117 interventional ones that give a count, is one of 28 that started in 2025, is one of 40 in phase 1, and was the 66th registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
5 of the studies testing orforglipron in Obesity that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
| NCT06972459Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity | 2027-08 |
| NCT06972472Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | 2027-08 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 22 studies testing orforglipron in Obesity, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 118 in Obesity:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to see how orforglipron affects the amount of body fat compared with placebo in participants with obesity or overweight. Participation in the study will last approximately 8 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have a (BMI)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive orforglipron orally
Drug: Orforglipron
Participants will receive placebo orally
Drug: Placebo
Administered orally
Also known as: LY3502970
Administered orally
Percent Change from Baseline in Visceral Adipose Tissue (VAT)
Time frame: Baseline, Week 36
Percent Change from Baseline in Energy Intake
Time frame: Baseline, Week 36
Percent Change from Baseline in Appetite
Time frame: Baseline, Week 36
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 36
Percent Change from Baseline in Fasting Total Cholesterol
Time frame: Baseline, Week 36
Percent Change from Baseline in High-Sensitivity C-Reactive Protein (hs-CRP)
Time frame: Baseline, Week 36
Change from Baseline in International Physical Activity Questionnaire-Long Form (IPAQ-L) Scores
Time frame: Baseline, Week 36
Plan to share: No
Ran from Feb 2025 to primary completion in Jan 2026, 11 months.
Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 11 months is above that.
Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orforglipron